The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic

The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic

Objective. Currently, the issues of the effect of anti-B cell therapy or inhibitor of interleukin 5 on the risk of COVID-19 infecting and outcomes in patients with ANCA-associated vasculitis (AAV) has not been completely studied. We present an analysis of the COVID-19 course and outcomes in AAV pati...

Full description

Saved in:
Bibliographic Details
Main Authors: T. V. Beketova, V. V. Babak, M. D. Suprun
Format: Article
Language:Russian
Published: IMA PRESS LLC 2021-03-01
Series:Научно-практическая ревматология
Subjects:
covid-19
rituximab
mepolizumab
в-cells
interleukin-5
anca-associated vasculitis
granulomatosis with polyangiitis
microscopic polyangiitis
eosinophilic granulomatosis with polyangiitis
Online Access:https://rsp.mediar-press.net/rsp/article/view/2988
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rsp.mediar-press.net/rsp/article/view/2988

Similar Items